Exenatide Twice Daily: Analysis of Effectiveness and Safety Data Stratified by Age, Sex, Race, Duration of Diabetes, and Body Mass Index

References

• . BYETTA® (exenatide) injection [package insert]. San Diego, CA: Amlyin Pharmaceuticals, Inc; 2010
   Google Scholar
• . Centers for Disease Control and Prevention. National diabetes fact sheet, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed February 28, 2011
   Google Scholar
• . Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559–569
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Burger J, Johns D, . Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333–2348
   PubMed Web of Science ®Google Scholar
• . Zinman B, Hoogwerf BJ, Durán García S, . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–485
   PubMed Web of Science ®Google Scholar
• . Moretto TJ, Milton DR, Ridge TD, . Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–1460
   PubMed Web of Science ®Google Scholar
• . Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long acting insulin to achieve glycemic control with minimal weight gain in patients with type 2 diabetes: results of Helping Evaluate Exenatide in patients with diabetes compared to Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11(12):1153–1162
   PubMed Web of Science ®Google Scholar
• . Gao Y, Yoon KH, Chuang LM, . Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract. 2009;83(1):69–76
   PubMed Web of Science ®Google Scholar
• . Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J. 2009;56(3):415–424
   PubMed Web of Science ®Google Scholar
• . Apovian CM, Bergenstal RM, Cuddihy RM, . Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123(5):e9–e17
   Google Scholar
• . Liutkus J, Rosas Guzman J, Norwood P, . A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010;12(12):1058–1065
   PubMed Web of Science ®Google Scholar
• . Gallwitz B, Böhmer M, Segiet T, . Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care. 2011;34(3):604–606
   PubMed Web of Science ®Google Scholar
• . Gill A, Hoogwerf BJ, Burger J, . Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9(6):6
   PubMedGoogle Scholar
• . DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010;33(5):951–957
   PubMed Web of Science ®Google Scholar
• . Kadowaki T, Namba M, Imaoka T, . Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest. 2011;2:210–217
   PubMed Web of Science ®Google Scholar
• . Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc. 2007;55(12): 2041–2044
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(3):163–170
   PubMedGoogle Scholar
• . Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2002;62(12):1805–1837
   PubMedGoogle Scholar
• . Erdmann E, Charbonnel B, Dormandy J, . Pioglitazone treatment in patients with type 2 diabetes and a history of myocardial infarction: subgroup analyses from PROactive stratified by gender, age, and duration of diabetes. Presented at: World Conference of Cardiology; September 2–6, 2006; Barcelona, Spain
   Google Scholar
• . Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab. 2007;9(1):31–38
   PubMedGoogle Scholar
• . Davidson JA, Lacaya LB, Jiang H, . Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocr Pract. 2010;16(5):818–828
   PubMedGoogle Scholar
• . Buysschaert M, Preumont V, Oriot PR, ; UCL Study Group for Exenatide. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36(5):381–388
   PubMed Web of Science ®Google Scholar
• . Buse JB, Klonoff DC, Nielsen LL, . Metabolic effects of two years of exenatide treatment on diabetes, obesity and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29(1):139–153
   PubMed Web of Science ®Google Scholar
• . Klonoff DC, Buse JB, Nielsen LL, . Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275–286
   PubMed Web of Science ®Google Scholar
• . Shomali M, Hale P, Zdravkovic M. Liraglutide, a once-daily human GLP-1 analog, improves glycemic control more than glimepiride in African American or black individuals with type 2 diabetes. Presented at: 114th National Medical Association Annual Convention and Scientific Assembly; July 25–29, 2009; Las Vegas, NV
   Google Scholar
• . Yang W, Chen L, Ji Q, . Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab. 2011; 13(1):81–88
   PubMed Web of Science ®Google Scholar
• . Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Curr Med Res Opin. 2008;24(9):2437–2447
   PubMed Web of Science ®Google Scholar